Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN.

We evaluated the association of hemostatic factors with insulin resistance in relation to reproductive hormones including FSH, estradiol, testosterone, and SHBG. SHBG was used to calculate the free estradiol index and free androgen index. We studied 3,200 women, aged 42-52 yr, in the Study of Women's Health Across the Nation, a prospective multiethnic study of the menopausal transition. We measured the hemostatic factors, fibrinogen, factor VIIc, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor type 1 (PAI-1), as well as glucose and insulin to calculate insulin resistance. After adjustment for body mass index, site, and ethnicity, SHBG was correlated with PAI-1 (partial r = -0.30) and t-PA (partial r = -0.12). Although testosterone was associated with t-PA (partial r = 0.13) and PAI-1 (partial r = 0.07), free androgen index was strongly correlated with t-PA (partial r = 0.18) and PAI-1 (partial r = 0.26). SHBG modified the association of hemostatic factors with insulin resistance. Women with greater insulin resistance had lower SHBG and higher PAI-1. Estrogen measures were not associated with insulin resistance. The influence of sex hormones on hemostatic factors and insulin resistance is poorly understood. SHBG, which influences the amount of bioavailable hormone, significantly modified the association of PAI-1 and t-PA with insulin resistance. The longitudinal Study of Women's Health Across the Nation will help us discern whether this interaction contributes to heart disease and diabetes among postmenopausal women.

[1]  Y. Aso,et al.  Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. , 2002, Metabolism: clinical and experimental.

[2]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[3]  J. Regensteiner,et al.  Impaired Fibrinolysis in Premenopausal Women and Age-matched Men with Type 2 Diabetes Mellitus: A Pilot Study , 2002, Journal of Investigative Medicine.

[4]  M. R. Toloi,et al.  Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. , 2001, International journal of fertility and women's medicine.

[5]  G. Giles,et al.  Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with Type 2 diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[6]  A. Gottsäter,et al.  Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. , 2001, Journal of internal medicine.

[7]  A. Ahlbom,et al.  Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[8]  David Morganstein,et al.  SWAN: A Multicenter, Multiethnic, Community-Based Cohort Study of Women and the Menopausal Transition , 2000 .

[9]  J. Kelsey,et al.  Menopause : biology and pathobiology , 2000 .

[10]  C. Glueck,et al.  Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. , 1999, Metabolism: clinical and experimental.

[11]  M. S. Khan,et al.  Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  J. Gilabert,et al.  Lipoprotein(a) Levels and Isoforms and Fibrinolytic Activity in Postmenopause – Influence of Hormone Replacement Therapy , 1999, Thrombosis and Haemostasis.

[13]  M. Aiach,et al.  Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  S. Haffner.  Progress in Population Analyses of the Insulin Resistance Syndrome , 1997, Annals of the New York Academy of Sciences.

[15]  C. Glueck,et al.  Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. , 1997, Metabolism: clinical and experimental.

[16]  D. Tousoulis,et al.  t-Plasminogen activator and von Willebrand factor in patients with unstable angina. , 1996, International journal of cardiology.

[17]  S. Haffner.  Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. , 1996, Hormone research.

[18]  H. Wendel,et al.  Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. , 1995, Circulation.

[19]  D. Levy,et al.  Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. , 1995, Circulation.

[20]  H. Adlercreutz,et al.  Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  K. Asplund,et al.  Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. , 1994, Metabolism: clinical and experimental.

[22]  N. Wald,et al.  Apolipoproteins and ischaemic heart disease: implications for screening , 1994, The Lancet.

[23]  A. Folsom,et al.  Association of Hormone-Replacement Therapy With Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[24]  S. Haffner,et al.  Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. , 1993, The Journal of clinical endocrinology and metabolism.

[25]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[26]  J. Nestler.  Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? , 1993, The Journal of clinical endocrinology and metabolism.

[27]  J. Cruickshank,et al.  The role of free fatty acids in regulating the tissue availability and synthesis of sex steroids. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  P. Pétra.  The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  J. Crave,et al.  Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  J. Clore,et al.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[31]  P. Vague,et al.  Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin , 1989, Thrombosis and Haemostasis.

[32]  S. J. Smith,et al.  The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. , 1989, Clinics in laboratory medicine.

[33]  Robert E. Jones,et al.  Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. , 1988, The Journal of clinical endocrinology and metabolism.

[34]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[35]  N. Duan.  Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[36]  R. Barbieri,et al.  Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. , 1983, American journal of obstetrics and gynecology.